Clinical Trials Logo

Clinical Trial Summary

Group A streptococcus (GAS) causes a variety of human infections. It is also an uncommon but serious cause of postpartum infections. In contrast to group B streptococcus (GBS) infection, which causes illness and death in newborns disproportionately more often than it does in mothers, perinatal GAS infection primarily affects mothers . Invasive GAS infection is defined by the isolation of GAS from a normally sterile site (e.g., blood) or by the isolation of GAS from a nonsterile site in the presence of the streptococcal toxic shock syndrome or necrotizing fasciitis. A postpartum case of invasive GAS is defined as isolation of GAS during the postpartum period, in association with a clinical postpartum infection (e.g., endometritis) or from either a sterile site or a wound infection.

Because of the burden and severity of invasive GAS infection, the Centers for Disease Control and Prevention (CDC) hosted a meeting in to formulate guidelines for responding to postpartum and postsurgical GAS infections. However, we could not find any recommendations for long-term follow-up of patients who had GAS infection subsequent to delivery or gynaecological procedures, or further recommendations regarding subsequent delivery or gynaecological invasive procedures. It is possible that women who had GAS as a cause of vaginal infection may have a tendency to be carriers of this organism, but this has never been proven. We believe it is of importance to determine if women who have had one infection may be long-term carriers which may pose a risk during future pregnancies.

The objective of the present study is to evaluate the incidence of long term gynaecological carrier state of patients who had GAS invasive infection following delivery, and to provide guidelines for follow-up and treatment of such patients.

The proposed study may answer the question whether this endogenous GAS origin represents chronic GAS carrier state, similar to the known GBS carrier state. As some of these patients had severe infections (sometimes life threatening) a protocol for long-term follow up and management is necessary in case an invasive procedure is done (IUD insertion, endometrial biopsy, curettage or delivery) in order to prevent recurrent infection. The information collected in the study will enable us to afford recommendations for follow up and prophylaxis in the future.


Clinical Trial Description

Research plan The study population will include patients diagnosed with GAS invasive infection following delivery or gynaecological procedures (such as endometrial biopsy, D&C or IUD insertion) at Hadassah university hospitals, and patients in whom an isolation of GAS from the vagina without infection was reported. The study will consist of two parts, prospective and retrospective.

1. Retrospective study

1. The records of all patients diagnosed with GAS infection/isolation in the past 3 years (2003-2005) will be reviewed. The estimated occurrence of GAS isolation from the genital tract in Hadassah hospital is 15 cases every year (Moses personal communication).

2. Patients' files will be reviewed for demographic and clinical variables associated with the development of GAS infection (age, parity, obstetric history), its clinical course and subsequent progress to septic shock, and the site of GAS isolation (blood, vaginal discharge, wound etc).

3. Additional information will be obtained from the patients in order to evaluate the incidence of gynaecological infections and risk factors for such infections. These include events of pelvic inflammatory disease, contraceptive methods, subsequent deliveries or D&C (a questionnaire is attached).

4. Vaginal cultures and pharyngeal swabs will be taken from all women with previous gynecological GAS infection/isolation participating in the study, in order to evaluate whether carriage of GAS in the vagina occurs.

2. emm typing Since we have the original isolates from women with invasive disease (those presenting with bacteremia) we will be able to compare the specific type isolate obtained in consequent cultures with the original isolate. Isolates will be compared by several known bacterial attributes such as emm type, T type, and the presence of genes for the different exotoxins. emm typing PCR of streptococcal isolates will be performed as previously described [11], according to the recommendations of the Division of Bacterial and Mycotic Diseases, Streptococcus pyogenes emm sequence database (http://www.cdc.gov/ncidod/biotech/strep/doc.htm).

3. Prospective study- In addition to the above patients, women presenting from the beginning of the study for two years, with an isolation of GAS from the vagina (even without overt disease), will be followed in order to evaluate the significance of such isolates. These isolates will be collected for comparison with surveillance cultures which will be taken in the future. Vaginal cultures and pharyngeal swabs will be taken every 2 months during the year. ;


Study Design

Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


NCT number NCT00299663
Study type Observational
Source Hadassah Medical Organization
Contact
Status Completed
Phase N/A
Start date February 2006
Completion date October 2011

See also
  Status Clinical Trial Phase
Completed NCT02052973 - Efficacy of Propolis Varnish Against Oral Biofilm Phase 1/Phase 2
Completed NCT01412801 - Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings Phase 2
Completed NCT00884728 - Evaluation of a Regional Healthy Skin Program in Remote Aboriginal Communities of Australia's Northern Territory N/A
Completed NCT01193920 - Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non Pregnant and Pregnant Women 18-40 Years of Age Phase 1/Phase 2
Terminated NCT00261742 - Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Streptococcal Dermatitis Phase 4
Completed NCT00169481 - A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine Phase 2
Completed NCT02270944 - Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine Phase 2
Completed NCT03055728 - Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis
Withdrawn NCT00598429 - Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure Phase 2
Completed NCT01030731 - Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease Phase 1
Completed NCT04100772 - Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above Phase 1
Completed NCT01118143 - Oral Health Literacy Tailored Communication N/A
Completed NCT01026740 - Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers Phase 1
Withdrawn NCT00330642 - Rapid Detection of Group B Streptococcus (Strep)-Labor and Delivery Study N/A
Completed NCT00646958 - Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections Phase 2
Completed NCT01026636 - A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age Phase 1
Completed NCT00514527 - A Study for Patients With Complicated Skin and Skin Structure Infections Phase 2
Completed NCT01026558 - A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients Phase 1
Completed NCT01156740 - Treatment of Group A Beta Hemolytic Streptococcal Pharyngitis in Children in Low Resource Settings N/A
Completed NCT04841369 - Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i) Phase 3